“Obesity Treatment” program sellers settle
This article was originally published in The Tan Sheet
Executive SummaryXavier Rodriguez and Santa Ana, Calif.-based Centro Natural Services, sellers of Centro Natural de Salud Obesity Treatment, settled with the Federal Trade Commission on a charge they made false and unsubstantiated claims their product leads to fast, substantial and permanent weight loss without dieting, FTC says Jan. 30. The settlement includes a judgment of nearly $2.4 million, but all but $20,000 is suspended because of the defendants' inability to pay. The settlement bans the defendants from representing a weight-loss product will lead to rapid weight loss without reducing caloric intake, or will cause users to "lose as much as a half-pound per day for multiple weeks and months," or "lose weight permanently"...
You may also be interested in...
In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.